President Trump signed an executive order creating a new division at the NIH aimed at coordinating research on women’s health. The first lady, Melania Trump, framed the initiative as an effort to accelerate diagnostics, treatment, and research into understudied conditions that disproportionately affect women. The order sets a 90-day timeline for establishing the new division; the source did not provide an organizational chart, staff plan, or formal mission statement beyond the administration’s public description.
Investigators quoted by the administration said the division will expand and coordinate research across life stages, strengthen inclusion of women and girls in clinical trials, and promote accountability for considering sex as a biological variable in NIH-funded studies. An NIH spokesperson told STAT on background that the new unit would work with the existing Office of Research on Women’s Health to achieve those aims. The source did not report specific research programs, funding lines, or prioritized disease areas for the new division.
The executive order also establishes a White House task force intended to convene senior officials to advance the initiative. White House chief of staff Susie Wiles is named to lead the task force. Other members listed in the source include cabinet secretaries, the acting FDA commissioner, and the newly confirmed CDC director. The first session was scheduled to convene the day the order was signed.
The source reported that the Department of Health and Human Services will cover administrative costs for the task force. The order’s text as cited in the article did not include a published charter, measurable objectives, or timelines for task force deliverables. The source therefore did not document how the task force will interact with NIH leadership, nor did it report mechanisms for external scientific input.
The article states plainly that the new division will not replace the current Office of Research on Women’s Health. Investigators and NIH staff will reportedly coordinate between the two entities, according to an NIH spokesperson speaking on background. The source did not disclose whether the new division will absorb personnel or budgets from existing institutes, whether it will administer grants directly, or what its authority will be relative to NIH institutes and centers.
Funding for women’s health research has been a contentious issue since the current administration returned to the White House, the source reports. Past actions—described in the article—have included special reviews of grant applications containing the word “women,” reductions in indirect cost rates, and other policy shifts that affected grant administration and diversity language in funding applications. The executive order specifies that HHS will pay for task force administrative costs, but the order did not state allocated research funds, whether Congress or NIH budget offices will be asked to reprogram existing funds, or whether new appropriations will be sought.
Researchers and academic leaders have been reacting to policy changes that, according to the source, disrupted women’s health science and pushed some investigators and investors to look elsewhere for support. The article cites public comments and prior reporting indicating that the NIH had signaled an upcoming refresh of its strategic plan for women’s health research emphasizing innovative methods, data science, and new technologies. Nicole Kleinstreuer, an NIH deputy director for program coordination, planning, and strategic initiatives, had predicted a fall refresh of that plan; the source does not report whether the new division alters or replaces the planned strategic update.
The article also references external commentary and reviews documenting clinical consequences traced to historic underinvestment—examples include higher rates of diagnostic delays, differential prescribing after hospital admission, and greater mortality after heart attacks for women. Those references are drawn from earlier publications and reviews cited by the source; the executive order itself does not present new clinical data.
Many operational questions remain unanswered in the reporting. The source did not provide details on the new division’s budget, staffing levels, grant-making authority, or how success will be measured. It did not publish a full charter, specific disease priorities, or a timeline for deliverables beyond the 90-day set-up target. The article also did not report whether the initiative has secured congressional support for research funding or how the division will handle potential overlaps with existing NIH institutes and centers.
The source named senior White House and federal officials who will participate in the task force, but it did not provide a public plan for scientific governance, peer review safeguards, or mechanisms to protect researcher independence. Those practical and procedural details will be essential to evaluate whether the announced division alters the trajectory of women’s health research funding and practice. The article ends by placing the announcement in the context of earlier policy shifts and calls for a biology-based reframing of women’s health, while leaving concrete operational milestones and accountability mechanisms to be documented in follow-up reporting.